Business Standard

Sun Pharma Q3 net profit up 5.2% as sales grow in India, US markets

Company says specialty products will continue as growth driver, will scale up investment for it

Sun Pharma
Premium

Sohini Das
Sun Pharmaceutical Industries posted a 5.2 percent year-on-year (YoY) rise in net profit for the third quarter of Financial Year 2022-23 to Rs 2,166 crore, riding on the back of sales in India and the US and an uptick in the global specialty portfolio.

The Mumbai-headquartered firm’s results were in line with analyst estimates, but the stock was down 1.5 percent on BSE on Tuesday.

Total sales grew by 13.1 per cent YoY to Rs 111,00 crore. Of this, India formulation sales were at Rs 3,391 crore, up 7.1 per cent over Q3 last year. US formulation sales were up

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jan 31 2023 | 4:49 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com